Please review the following Faculty information, and then select Step 3 to start the Activity.

 

Faculty

David N. Neubauer, MD, Program Chair
Assistant Professor
Department of Psychiatry
Associate Director, Johns Hopkins Sleep Disorders Center
The Johns Hopkins University School of Medicine
Baltimore, MD

Stephen A. Brunton, MD, Program Co-Chair
Adjunct Clinical Professor
Department of Family Medicine
University of North Carolina at Chapel Hill
Chapel Hill, NC
Director of Faculty Development
Cabarrus Family Residency Program
Concord, NC

Christopher J. Earley, MB, BCh, PhD, FRCP(I)
Professor of Neurology
Co-Director, The Johns Hopkins Center for Restless Legs Syndrome
Associate Director, Johns Hopkins Sleep Disorders Center
The Johns Hopkins University School of Medicine
Baltimore, MD

 

Faculty Disclosures

As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of The Johns Hopkins University School of Medicine to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The presenting faculty reported the following:

Dr. Neubauer has participated as a consultant for Neurocrine Biosciences, sanofi-aventis, U.S., and Takeda, and has participated in Speaker’s Bureau Meetings for sanofi-aventis, U.S., and Takeda.

Dr. Brunton has participated in advisory boards for Abbott Laboratories, Allergan, Amylin Pharmaceuticals, Bristol-Myers Squibb, Novo Nordisk, sanofi-aventis, U.S., and Sciele Pharma.

Dr. Earley has nothing to disclose.

Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

In this case-based review, Dr. Earley and Dr. Neubauer both discuss unlabeled/unapproved uses of benzodiazepines, opioids, and alpha-2-delta calcium-channel modulators.